Actively Recruiting
Phase 2 Study of Neoadjuvant Chemo-immunotherapy with Tislelizumab for Adults with Stage III PD-L1 Positive Non-Small Cell Lung Cancer
Led by Fondazione Ricerca Traslazionale · Updated on 2025-12-04
30
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a new treatment approach for adults who are current or former smokers diagnosed with stage III non-small cell lung cancer NSCLC that is positive for PD-L1 and does not have specific genetic alterations EGFR, ALK, ROS1, RET. This phase 2, single-arm study aims to assess the use of neoadjuvant chemo-immunotherapy to improve treatment outcomes in this group of patients. Participants will receive three cycles of neoadjuvant chemo-immunotherapy tailored to their NSCLC type. Following this treatment, their disease will be reassessed with imaging and pathological evaluation of lymph nodes. Patients whose lymph nodes show no remaining cancer may undergo surgery followed by up to one year of maintenance treatment with the drug tislelizumab. Those with persistent lymph node involvement will receive chemoradiotherapy as standard care. Throughout the study, patients will undergo comprehensive assessments including chest CT, PET-CT, brain MRI, and pathological evaluations before and after neoadjuvant therapy. Researchers will monitor the success of surgery and disease status over three years, focusing on complete tumor removal. Safety and effectiveness of the treatment approach will be tracked during follow-up, which includes adjuvant therapy and routine clinical care.
CONDITIONS
Brief Title
Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC)
Research Team
F
Federico Cappuzzo, Medical Oncology
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here